EGFR and colorectal cancer: Moreover, as a number of studies had proved Kirsten rat sarcoma viral oncogene homolog (KRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) oncogene mutations are recognized biomarkers that predict lack of response to anti-epidermal growth factor receptor (EGFR) antibody therapies and are associated with a worse prognosis in patients with metastatic adenocarcinoma in colorectal cancer [9-11].